$PSNL news
The latest PSNL stock news: headlines, filings, AI summaries and sentiment for $PSNL, updated around the clock.
- Personalis, Inc. - 10-Q Filing
- Personalis, Inc. - 8-K Filing
- Tempus AI Reports Q3 2026 Growth Driven by Oncology Volume and Data Licensing
- Personalis, Inc. - 8-K Filing
- BTIG Downgrades Personalis Following Tempus Acquisition
- Tempus AI Outlines Growth Strategy Fueled by Pricing Increases and Data Licensing Expansion
- Tempus AI shares rise following analyst upgrades
- Tempus AI's Acquisition of Personalis Gains Strategic Momentum Following Melanoma Trial Success
- Tempus AI Director Sells Stock Before Significant Rally
- Tempus AI Set to Report Q2 Earnings Amid Pending Acquisition
- Tempus Acquires Personalis for $1.5 Billion in Bid to Control Cancer-Test Market
- Tempus Acquires Personalis for $1.5 Billion to Expand Cancer Testing Capabilities
- Tempus Agrees to Acquire Cancer Test Maker Personalis for $1.5 Billion
- Tempus AI Acquires Cancer-Monitoring Firm Personalis for $1.5 Billion
- Tempus AI Acquires Personalis in $1.5 Billion Precision Oncology Deal
- Personalis, Inc. - 8-K Filing
- Tempus AI Acquires Personalis to Expand MRD Testing and Biopharma Capabilities
- Tempus AI Acquires Cancer-Monitoring Firm Personalis for $1.5 Billion
- Tempus AI Acquires Personalis in $1.5 Billion Deal to Expand Cancer Testing Capabilities
- Personalis, Inc. - 8-K Filing
- Merck Shows Takeover Interest in Personalis
- Personalis CEO Sells Shares Worth $1.1 Million
- Personalis CEO Sells $1.1 Million Worth of Shares
- Personalis, Inc. - 8-K Filing
- Personalis Receives Expanded Medicare Coverage for NeXT Personal Test
- Personalis Reports Q1 2026 Earnings: Clinical Test Growth Drives Strategic Revenue
- Personalis, Inc. - 10-Q Filing
- Personalis, Inc. - 8-K Filing